Jean-Louis Pinquier
Jean-Louis Pinquier
DECISIONS R&D consulting
Verified email at decisions-rd.com
Title
Cited by
Cited by
Year
Effect of intrapulmonary tetrahydrocannabinol administration in humans
L Zuurman, C Roy, RC Schoemaker, A Hazekamp, J Den Hartigh, ...
Journal of psychopharmacology 22 (7), 707-716, 2008
1452008
Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate—insight into its mechanisms of action and a tool for clinical …
A Strougo, L Zuurman, C Roy, JL Pinquier, JMA Van Gerven, AF Cohen, ...
Journal of Psychopharmacology 22 (7), 717-726, 2008
712008
Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation
X Bertagna, H Escourolle, JL Pinquier, J Coste, MC Raux-Demay, ...
The Journal of Clinical Endocrinology & Metabolism 78 (2), 375-380, 1994
611994
Synthesis and in vivo imaging properties of [11C] befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A
F Dolle, H Valette, Y Bramoulle, I Guenther, C Fuseau, C Coulon, ...
Bioorganic & medicinal chemistry letters 13 (10), 1771-1775, 2003
542003
The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers
E Legangneux, J McEwen, KA Wesnes, L Bergougnan, N Miget, M Canal, ...
Journal of Psychopharmacology 14 (2), 164-171, 2000
482000
Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not …
S Urien, JL Pinquier, B Paquette, P Chaumet-Riffaud, JR Kiechel, ...
Journal of Pharmacology and Experimental Therapeutics 242 (1), 349-353, 1987
481987
Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625
L Zuurman, C Roy, RC Schoemaker, A Amatsaleh, L Guimaeres, ...
Journal of Psychopharmacology 24 (3), 363-371, 2010
432010
Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C] befloxatone
M Bottlaender, F Dollé, I Guenther, D Roumenov, C Fuseau, Y Bramoulle, ...
Journal of Pharmacology and Experimental Therapeutics 305 (2), 467-473, 2003
392003
Relationship between low‐density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid‐lowering strategies
J Rey, F Poitiers, T Paehler, A Brunet, AT DiCioccio, CP Cannon, ...
Journal of the American Heart Association 5 (6), e003323, 2016
352016
Role of alpha‐1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin
S Urien, E Albengres, JL Pinquier, JP Tillement
Clinical Pharmacology & Therapeutics 39 (6), 683-689, 1986
351986
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
British journal of clinical pharmacology 76 (1), 65-77, 2013
252013
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
British journal of clinical pharmacology 76 (1), 65-77, 2013
252013
Pharmacological criteria for risk-benefit evaluation of NSAIDs
E Albengres, JL Pinquier, P Riant, F Bree, S Urien, J Barre, JP Tillement
Scandinavian Journal of Rheumatology 17 (sup73), 3-15, 1988
231988
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid
US Patent App. 13/633,496, 2013
202013
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid
US Patent App. 13/633,496, 2013
202013
Inhibition of histamine‐induced skin wheal and flare after 5 days of mizolastine
JL Pinquier, H Caplain, MJ Cabanis, C Dubruc, A Stalla‐Bourdillon, ...
The Journal of Clinical Pharmacology 36 (1), 72-78, 1996
191996
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid
US Patent App. 13/633,563, 2013
182013
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
J Stechl, I Nowotny, C Pfeiffer, JL Pinquier, J Msihid
US Patent App. 13/633,563, 2013
182013
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
P Ruus, L Silvestre, P Miossec, JL Pinquier, A Hincelin-mery
US Patent App. 13/469,633, 2013
182013
Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to …
J Rey, F Poitiers, T Paehler, A Brunet, JL Pinquier, C Hanotin, B Sasiela
Journal of the American College of Cardiology 63 (12S), A1375-A1375, 2014
132014
The system can't perform the operation now. Try again later.
Articles 1–20